Simone L Verweij1, Maurice W J de Ronde2, Rutger Verbeek1, S Matthijs Boekholdt3, R Nils Planken4, Erik S G Stroes1, Sara-Joan Pinto-Sietsma5. 1. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 4. Department of Radiology and Nuclear medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 5. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: pintosj@gmail.com.
Abstract
BACKGROUND: Elevated lipoprotein(a) (Lp(a)) levels are associated with increased risk for atherosclerotic cardiovascular disease (ASCVD). Individuals with a family history of premature ASCVD are at increased cardiovascular risk with concomitantly a higher burden of (subclinical) atherosclerosis. However, whether Lp(a) contributes to the increased atherosclerotic burden in these individuals remains to be established. OBJECTIVE: In this study, we evaluated the association between Lp(a) levels and coronary atherosclerotic burden, assessed by coronary arterty calcium (CAC) scores, in asymptomatic individuals with a family history of premature ASCVD. METHODS: Lp(a) levels and other ASCVD risk factors were assessed in 432 individuals with premature ASCVD and in 937 healthy asymptomatic family members. CAC scores were only measured in asymptomatic family members. RESULTS: In this cohort, 16% had elevated Lp(a) levels, defined as ≥ 50 mg/dL. Among healthy family members, elevated Lp(a) levels were associated with both absolute CAC scores of ≥ 100 (odds ratio [OR] 1.79 [95% confidence interval {CI} 1.13-2.83]) as well as with age- and gender-corrected CAC scores ≥ 80th percentile (OR 1.69 [95% CI 1.14-2.50]). This coincides with a higher prevalence of cardiovascular events (OR 1.48 [95% CI 1.11-2.01]) in the whole cohort. CONCLUSION: Elevated Lp(a) levels were associated with higher CAC scores, both absolute as well as age- and gender-corrected percentiles, in individuals with a family history of premature ASCVD. These data imply that Lp(a) accelerates progression of atherosclerosis in these individuals, thereby contributing to their increased ASCVD risk.
BACKGROUND: Elevated lipoprotein(a) (Lp(a)) levels are associated with increased risk for atherosclerotic cardiovascular disease (ASCVD). Individuals with a family history of premature ASCVD are at increased cardiovascular risk with concomitantly a higher burden of (subclinical) atherosclerosis. However, whether Lp(a) contributes to the increased atherosclerotic burden in these individuals remains to be established. OBJECTIVE: In this study, we evaluated the association between Lp(a) levels and coronary atherosclerotic burden, assessed by coronary arterty calcium (CAC) scores, in asymptomatic individuals with a family history of premature ASCVD. METHODS:Lp(a) levels and other ASCVD risk factors were assessed in 432 individuals with premature ASCVD and in 937 healthy asymptomatic family members. CAC scores were only measured in asymptomatic family members. RESULTS: In this cohort, 16% had elevated Lp(a) levels, defined as ≥ 50 mg/dL. Among healthy family members, elevated Lp(a) levels were associated with both absolute CAC scores of ≥ 100 (odds ratio [OR] 1.79 [95% confidence interval {CI} 1.13-2.83]) as well as with age- and gender-corrected CAC scores ≥ 80th percentile (OR 1.69 [95% CI 1.14-2.50]). This coincides with a higher prevalence of cardiovascular events (OR 1.48 [95% CI 1.11-2.01]) in the whole cohort. CONCLUSION: Elevated Lp(a) levels were associated with higher CAC scores, both absolute as well as age- and gender-corrected percentiles, in individuals with a family history of premature ASCVD. These data imply that Lp(a) accelerates progression of atherosclerosis in these individuals, thereby contributing to their increased ASCVD risk.
Authors: Nicolas Perrot; Sébastien Thériault; Christian Dina; Hao Yu Chen; S Matthijs Boekholdt; Sidwell Rigade; Audrey-Anne Després; Anthony Poulin; Romain Capoulade; Thierry Le Tourneau; David Messika-Zeitoun; Mikaël Trottier; Michel Tessier; Jean Guimond; Maxime Nadeau; James C Engert; Kay-Tee Khaw; Nicholas J Wareham; Marc R Dweck; Patrick Mathieu; Philippe Pibarot; Jean-Jacques Schott; George Thanassoulis; Marie-Annick Clavel; Yohan Bossé; Benoit J Arsenault Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: Brian T Steffen; George Thanassoulis; Daniel Duprez; James H Stein; Amy B Karger; Mathew C Tattersall; Joel D Kaufman; Weihua Guan; Michael Y Tsai Journal: Arterioscler Thromb Vasc Biol Date: 2019-03 Impact factor: 8.311
Authors: Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet Journal: Metabolism Date: 2021-01-07 Impact factor: 8.694
Authors: Young Hak Chung; Byoung-Kwon Lee; Hyuck Moon Kwon; Pil-Ki Min; Eui-Young Choi; Young Won Yoon; Bum-Kee Hong; Se-Joong Rim; Jong-Youn Kim Journal: Medicine (Baltimore) Date: 2021-03-05 Impact factor: 1.817
Authors: Maximillian A Rogers; Samantha K Atkins; Kang H Zheng; Sasha A Singh; Sarvesh Chelvanambi; Tan H Pham; Shiori Kuraoka; Erik S G Stroes; Masanori Aikawa; Elena Aikawa Journal: Front Cardiovasc Med Date: 2022-01-28
Authors: Yannick Kaiser; Sunny S Singh; Kang H Zheng; Rutger Verbeek; Maryam Kavousi; Sara-Joan Pinto; Meike W Vernooij; Eric J G Sijbrands; S Matthijs Boekholdt; Yolanda B de Rijke; Erik S G Stroes; Daniel Bos Journal: Heart Date: 2021-05-07 Impact factor: 5.994